Sangamo Therapeutics (SGMOQ) Cash & Current Investments (2010 - 2025)

Sangamo Therapeutics' Cash & Current Investments history runs 16 years deep, the most recent figure standing at $20.9 million for Q4 2025.

• On a quarterly basis, Cash & Current Investments fell 50.03% year-over-year to $20.9 million in Q4 2025; TTM through Dec 2025 was $20.9 million, a 50.03% decrease from a year earlier, with the FY2025 full-year figure at $20.9 million, down 50.03% from the prior year.
• Cash & Current Investments retreated to $20.9 million in Q4 2025 per SGMOQ's latest filing, from $30.5 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $587.1 million in Q1 2021 and bottomed at $20.9 million in Q4 2025.
• The 5-year median for Cash & Current Investments is $89.3 million (2022), against an average of $182.1 million.
• Across the five-year window, Cash & Current Investments surged 63.93% in 2021 and plunged 80.58% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $376.5 million in 2021, then sank by 73.33% to $100.4 million in 2022, then tumbled by 55.0% to $45.2 million in 2023, then declined by 7.27% to $41.9 million in 2024, then plunged by 50.03% to $20.9 million in 2025.
• Per Business Quant, the three latest SGMOQ Cash & Current Investments figures stand at $20.9 million (Q4 2025), $30.5 million (Q3 2025), and $38.3 million (Q2 2025).